Single answer

Is Adagene Inc (ADAG) a buy or sell?

4starter turns market data into one clear verdict you can act on.

Hold
$3.17
+0.0145 (+0.46%)
Quote updated: 2026-02-26 15:51 UTC
Trend today
+0.46%
Up today
Volume vs avg
94.25%
0.06x under average
Target gap
57.51%
above current price
Signal updated
Not available
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Add to watchlist

Create a free account to save tickers and track your signals.

Log in to turn on watchlist alerts.

Decision snapshot

Everything you need to act fast, in one glance.

4starter signal
Hold
Not available

Powered by momentum, volatility, and trend inputs.

Analyst target gap
57.51%
$1.826 above current price

Consensus target $5.00.

Volume vs average
94.25%
under average

7,217 vs 125,616 average (0.06x normal).

What is the conclusion?

Right now our advanced algorithms say:

YES

Do analysts agree?

We compare consensus targets with today's price.

YES

Consensus target for Adagene Inc is $5.00, which is $1.826 (57.51%) above the current price today's price.

Low target: $5.00 | High target: $5.00

Company snapshot

A quick overview of the business and its public profile.

Adagene Inc a clinical stage biopharmaceutical company engages in the research development and production of monoclonal antibody drugs for cancers The companys product candidates include ADG106 a human ligandblocking agonistic antiCD137 monoclonal antibodies mAbs that is in Phase 1b2 clinical trials for the treatment advanced solid tumors and nonHodgkins lymphoma ADG126 a fullyhuman antiCTLA4 mAb that is in Phase 1 clinical trial for the treatment advancedmetastatic solid tumors and ADG116 a human ligandblocking antiCTLA4 mAb which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors It also offers ADG104 an antiPDL1 mAb that is in Phase 2 clinical development ADG125 a novel antiCSF1R mAb which is in Phase I clinical trial ADG206 a masked Fc engineered antiCD137 agonistic POWERbody which is in preclinical ADG153 a masked antiCD47 IgG1 SAFEbody which is in preclinical stage for the treatment hematologic and solid tumors ADG138 novel HER2xCD3 POWERbody which is in preclinical for the treatment HER2expressing solid tumors and ADG152 a CD20xCD3 POWERbody which is in preclinical stage for the treatment offtumor toxicities The company was incorporated in 2011 and is headquartered in Suzhou China

Website: https://www.adagene.com

Rates and inflation backdrop

US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.

Inflation sensitivity

Debt ratio: 0.10. Cash flow to debt ratio: -4.99. Net profit margin: -37,235.60%. Inflation risk score: high (0.85/1).

Dividend history check

We cannot find any recorded dividends paid in our systems.

Trading liquidity

No, the average daily trading liquidity for Adagene Inc is $297,581. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

10-year return check

We cannot find data for Adagene Inc 10 years ago, but if you had invested on 2021-02-09 when the price was $29.99, you would have made a loss of $26.83 per share or 89.46%.

Why this answer

We combine price momentum, volatility, and trend signals to simplify the decision to one word.

1

Signal engine scans price, trend, and momentum indicators.

2

Targets and sentiment are checked against the live quote.

3

We keep the output simple: buy, sell, or hold.

Analyst consensus

How Wall Street targets compare to today's price.

$5.00
$1.826 (57.51%) above the current price
Range: $5.00 - $5.00

FAQ

Today's 4starter signal is Hold. That means the signal is mixed right now.

Quotes and targets refresh throughout the trading day, with the latest timestamp shown on the page.

It blends momentum, trend, and volatility indicators into a single decision-oriented verdict.